Tchem METAP2 Methionine aminopeptidase 2

Protein Summary

Description

Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). The catalytic activity of human METAP2 toward Met-Val peptides is consistently two orders of magnitude higher than that of METAP1, suggesting that it is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo. Protects eukaryotic initiation factor EIF2S1 from translation-inhibiting phosphorylation by inhibitory kinases such as EIF2AK2/PKR and EIF2AK1/HCR. Plays a critical role in the regulation of protein synthesis. The protein encoded by this gene is a member of the methionyl aminopeptidase family. The encoded protein functions both by protecting the alpha subunit of eukaryotic initiation factor 2 from inhibitory phosphorylation and by removing the amino-terminal methionine residue from nascent proteins. Increased expression of this gene is associated with various forms of cancer, and the anti-cancer drugs fumagillin and ovalicin inhibit the protein by irreversibly binding to its active site. Inhibitors of this gene have also been shown to be effective for the treatment of obesity. A pseudogene of this gene is located on chromosome 2. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2015]

Uniprot Accession IDs

• P50579
• B2RDI8
• B4DUX5
• G3XA91
• Q8NB11
• MAP 2

Gene Name

• METAP2

Ensembl ID

• ENST00000261220
• ENSP00000261220
• ENSG00000111142
• ENST00000323666
• ENSP00000325312
• ENST00000546753
• ENSP00000448169

Symbol

• MNPEP
• P67EIF2
• MAP2
• MNPEP
• p67eIF2

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
transcription factor perturbation	0.91
kinase perturbation	0.88
disease perturbation	0.87
virus perturbation	0.83
drug	0.79

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 223.79   (req: < 5)

Gene RIFs: 24   (req: <= 3)

Antibodies: 248   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 223.79   (req: >= 5)

Gene RIFs: 24   (req: > 3)

Antibodies: 248   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 10

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 659

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drugs: 2